EGFRI Induced Acneiform Lesions clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
open to eligible people ages 18 years and up
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions
at UCLA
Our lead scientists for EGFRI Induced Acneiform Lesions research studies include Zev Wainberg.
Last updated: